ALKERMES | ALKS - Loan Capital


ALKERMES reported $1.48B in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Acadia Pharmaceuticals USD 0 0 Mar/2025
ALKERMES USD 1.48B 7.23M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 47.86B 8.49B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
J&J USD 37.34B 183M Jun/2026
Malin Corporation EUR 0 0 Dec/2024
Merck USD 51.08B 4.41B Jun/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Otsuka Holdings JPY 164.66B 301M Jun/2026
Ovoca Bio EUR 0 0 Jun/2021
Pfizer USD 60.5B 70M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025